PolyPid said it has entered a key regulatory transition for D-PLEX100, with its rolling NDA submission to the FDA underway and the remaining clinical module expected to be filed imminently. The ...

Image source: The Motley Fool. PolyPid (NASDAQ:PYPD) is nearing completion of its rolling NDA for D-PLEX100, with imminent clinical module submission poised to trigger the FDA review process. The ...

Sangamo Therapeutics Inc (SGMO) has made progress in the rolling submission of the BLA for ST920 in Fabry disease, with the first two modules submitted. The FDA has reaffirmed that an additional ...

Chief Operating Officer, U.S. Warshavsky stated that recent SHIELD II data, showing a "64% relative risk reduction with a P value of 0.0103 in severe wound events," directly aligns with hospital and ...

The Clinical Genetics and Genetic Counseling Service at Fred Hutch Cancer Center offers cancer risk assessment for people who are at high risk of developing cancer because of their personal history ...

Sangamo Therapeutics missed both EPS and revenue forecasts, highlighting financial struggles. The company’s stock transitioned to the OTCQB market due to Nasdaq delisting, indicating financial ...

Good afternoon, and welcome to Sangamo Therapeutics First Quarter 2026 Teleconference Call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to ...

Greetings, and welcome to PolyPid's First Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this call is recorded. And I would now like to introduce your host for today's ...

Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $0.01. Operator: Good afternoon, and welcome to Sangamo Therapeutics First Quarter 2026 ...

Sangamo Therapeutics reported its Q1 2026 earnings with a notable miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.08, falling short of the expected -$0.06 ...

Structural imaging based on magnetic resonance is an integral part of the clinical assessment of patients with suspected Alzheimer dementia. Prospective data on the natural history of change in ...

In the clinic, tumour dormancy is observed in local recurrences or metastases. It usually refers to the time after treatment that a patient is asymptomatic but still carries local remnant or ...